Skip to content

GLP-1 Medications for Polycystic Ovary Syndrome (PCOS)

Hormonal disorder causing enlarged ovaries with small cysts. GLP-1s reduce insulin resistance, a root driver of PCOS, improving menstrual regularity and fertility. Polycystic Ovary Syndrome (PCOS) affects 6-12% of women of reproductive age, and GLP-1 medications offer a clinically proven treatment option.

Prevalence

6-12% of women of reproductive age

Recommended Medications

2

Treatment Type

GLP-1 Agonist

How GLP-1 Medications Help with Polycystic Ovary Syndrome (PCOS)

GLP-1s reduce insulin resistance, a root driver of PCOS, improving menstrual regularity and fertility. For patients with polycystic ovary syndrome (pcos), GLP-1 medications address the underlying metabolic dysfunction that makes weight management difficult. Clinical trials have consistently shown that GLP-1 treatment produces significant improvements in both weight and condition-specific outcomes.

Recommended GLP-1 Medications for Polycystic Ovary Syndrome (PCOS)

Based on clinical evidence, the following GLP-1 medications are recommended for patients with polycystic ovary syndrome (pcos):

Start Free Assessment This is an affiliate link. We may earn a commission at no extra cost to you.

Polycystic Ovary Syndrome (PCOS) & GLP-1 FAQ

Can GLP-1 medications help with polycystic ovary syndrome (pcos)?

Yes. GLP-1s reduce insulin resistance, a root driver of PCOS, improving menstrual regularity and fertility. Clinical evidence supports the use of GLP-1 medications like semaglutide and tirzepatide for patients with polycystic ovary syndrome (pcos).

Which GLP-1 medication is best for polycystic ovary syndrome (pcos)?

Semaglutide is often the first-line recommendation for polycystic ovary syndrome (pcos) due to its strong clinical evidence. Your provider will evaluate your specific situation to determine the best option.

How much weight can I lose with GLP-1 if I have polycystic ovary syndrome (pcos)?

Weight loss results are generally comparable to clinical trial averages (15-22% of body weight), though individual results vary based on the severity of polycystic ovary syndrome (pcos) and other health factors.

How prevalent is polycystic ovary syndrome (pcos)?

Polycystic Ovary Syndrome (PCOS) affects 6-12% of women of reproductive age. GLP-1 medications represent a significant treatment advancement for patients dealing with this condition alongside excess weight.

Other Conditions Treated with GLP-1